NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Poor Man -,

From a business perspective that seems to be a good way to look at this. I believe NWBO still wants to protect L/Direct combo research for certain potential situations where properly activated but reduced pace or more complete immune response is more desirable as synergy was noted in early DC research between intradermal and intratumoral injections by Triozzi et al. This may be taken care of by other combos but safety would likely not be an issue with this one. This synergy seems to point to a more complete local and systemic response. I expect their thinking about this to be clarified before being handed over Carte Blanche as progress with L is made. Best wishes.